Affitech
Discovery and development of proprietary antibody-based therapeutic products
Affitech is a privately held biotechnology company, which was founded in 1997 by a group of Norwegian and German Scientists (Ole Jorgen Marvik, Melvyn Little, Martin Welschof).
In September 2000, Affitech acquired Actigen Ltd (Cambridge, UK) from Active Biotech AB (Lund, Sweden).
In December 2001, Affitech established a wholly-owned subsidiary in the San Francisco Bay Area, USA.
Martin Welschof (CEO)
Rathin C. Das (CBO)
Björn Cochlovius (Director R&D)
Hans Petter Tjeldflaat (Director Finance)
Oslo Research Park
Gaustadalléen 21
N-0349 Oslo
Norway
Phone: +47-22958758
Fax: +47-22958358
Isolated human monoclonal antibodies
Related patents
Related news
- Affitech Acquires Pharmexa’s Diabody Technology
- Affitech to Help New Norwegian Cancer Stem Cell Center Speed up Biomarker Discovery
- Affitech Appoints Sergej Kiprijanov New Head of Research
- Affitech Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as Avastin® in Preclinical Cancer Models
- Affitech Appoints New Board Member
- Affitech Signs Antibody Research and Licensing Agreement with Roche
- Affitech Moves to Further Strengthen Human Antibody Intellectual Property Position
- Affitech Contracts With ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate
- Affitech to Play Key Role in Major EU Embryonal Tumor Pipeline Project
- Affitech Renews Exclusive Worldwide Phage Display License From DKFZ
- Affitech Raises NOK 86 Million ($ 13 Million) in Private Placement